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Abstract
Introduction: Extracorporeal membrane oxygenation (ECMO) is a supportive therapy, with its success dependent
on effective drug therapy that reverses the pathology and/or normalizes physiology. However, the circuit that
sustains life can also sequester life-saving drugs, thereby compromising the role of ECMO as a temporary support
device. This ex vivo study was designed to determine the degree of sequestration of commonly used antibiotics,
sedatives and analgesics in ECMO circuits.
Methods: Four identical ECMO circuits were set up as per the standard protocol for adult patients on ECMO. The
circuits were primed with crystalloid and albumin, followed by fresh human whole blood, and were maintained at
a physiological pH and temperature for 24 hours. After baseline sampling, fentanyl, morphine, midazolam,
meropenem and vancomycin were injected into the circuit at therapeutic concentrations. Equivalent doses of
these drugs were also injected into four polyvinylchloride jars containing fresh human whole blood for drug
stability testing. Serial blood samples were collected from the ECMO circuits and the controls over 24 hours and
the concentrations of the study drugs were quantified using validated assays.
Results: Four hundred samples were analyzed. All study drugs, except meropenem, were chemically stable. The
average drug recoveries from the ECMO circuits and the controls at 24 hours relative to baseline, respectively, were
fentanyl 3% and 82%, morphine 103% and 97%, midazolam 13% and 100%, meropenem 20% and 42%,
vancomycin 90% and 99%. There was a significant loss of fentanyl (p = 0.0005), midazolam (p = 0.01) and
meropenem (p = 0.006) in the ECMO circuit at 24 hours. There was no significant circuit loss of vancomycin at
24 hours (p = 0.26).
Conclusions: Sequestration of drugs in the circuit has implications on both the choice and dosing of some drugs
prescribed during ECMO. Sequestration of lipophilic drugs such as fentanyl and midazolam appears significant and
may in part explain the increased dosing requirements of these drugs during ECMO. Meropenem sequestration is
also problematic and these data support a more frequent administration during ECMO.
Introduction
Extracorporeal membrane oxygenation (ECMO) is
increasingly being used in adult patients with cardiac or
respiratory failure refractory to conventional therapy or
with both. ECMO can be an effective bridge to recovery,
clinical decision-making, long-term mechanical cardiac
support, and, less commonly, heart/lung transplantation
[1]. Patients on ECMO receive multiple drugs that
include sedatives and analgesics, antibiotics, anticoagu-
lants, and vasoactive agents. The success of ECMO may
rely on the successful use of these therapies. Although
sedatives and vasoactive agents can be titrated to effect
clinically, there are no reliable clinical markers to guide
antibiotic therapy in critically ill patients. Antibiotics are
commonly prescribed in patients on ECMO, and subop-
timal therapy may result in therapeutic failure [2-5],
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adversely affecting patient outcomes. Despite the avail-
able endpoints for titration of sedation and analgesia in
the intensive care unit [6] and efforts to minimize seda-
tive drug use in this group [7], studies have reported
escalating sedative doses over time in patients on
ECMO [8-10].
There are limited data to guide drug therapy in adult
patients receiving ECMO. Data from neonatal circuit
experiments reveal significant sequestration of drugs in
the ECMO circuit [11,12], and the extent of loss
depends upon their physicochemical properties, type
and age of the circuit, and the pumps used [10,13].
Pharmacokinetic (PK) studies in neonates [11,12] have
consistently demonstrated increased volume of distribu-
tion (Vd) and decreased drug clearance (CL) during
ECMO. Sequestration of drugs in the circuit appears to
add to the increased Vd along with other factors related
to critical illness, such as third spacing [11,14]. These
studies in neonates highlight the important issue of
altered PK during ECMO, but further extrapolation of
the neonatal data to adult intensive care practice may
not be relevant given the developmental and physiologi-
cal differences between the two populations [15].
Systematic research in this area by using contemporary
circuitry is required to develop evidence-based dosing
guidelines for antibiotic therapy in adult patients receiv-
ing ECMO. The aim of this study was to describe the dis-
position of the analgesics fentanyl and morphine, the
sedative agent midazolam, and the antibiotics merope-
nem and vancomycin in an ex vivo ECMO circuit model.
Materials and methods
Ethics approval was obtained from the local Human
Research Ethics Committee (HREC/12/QPCH/90).
Extracorporeal membrane oxygenation circuits
The methods for the development of our ex vivo model
of ECMO have been published previously [16]. Four
permanent life support (PLS) ECMO circuits (Maquet
Cardiopulmonary AG, Rastatt, Germany) were used.
Each circuit consisted of Bioline tubing™, a PLS Quad-
rox D oxygenator, and RotaFlow pump head. A reservoir
bladder (R-38; Medtronic Pty Ltd, Minneapolis, MN,
USA) was added to allow fluid sampling from the closed
circuit. The circuits were primed with 900 mL of Plas-
malyte P-148 (Baxter Healthcare, Toongabbie, New
South Wales, Australia) and then exchanged for 500 mL
of Albumex 4 (Human Albumin 40 g/L; CSL Limited,
Broadmeadows, Victoria, Australia). Porcine mucous
heparin (Pfizer Australia, West Ryde, New South Wales,
Australia) was added to the circuits (5,000 U). Fresh
whole human blood (less than 5 days old, mean volume
of 420 ± 52 mL, provided by Australian Red Cross
Blood Service, Melbourne, Victoria, Australia) was used
for the final prime, and the circuits were pressurized to
obtain post-oxygenator pressures of 230 to 250 mm Hg.
The final volume of the pressurized circuit was 668 ±
1.7 mL, and the mean hemoglobin value was 64 ± 13 g/L.
The mean total protein and albumin concentration in the
circuit were 33 ± 2.5 g/L and 25 ± 0.9 g/L, respectively.
Activated clotting time was maintained between 220 and
250 seconds. A centrifugal pump (Jostra RotaFlow;
Maquet Cardiopulmonary AG) was used to maintain a
circuit flow rate of 4 to 5 L/minute. Oxygen tension in
the circuit blood was maintained between 150 and
200 mm Hg. Circuit temperature was maintained at
37°C. Carbon dioxide gas or sodium bicarbonate solution
was added to the circuit to maintain the pH of the circu-
lating blood in the range of 7.25 to 7.55. Fentanyl (20 μg),
morphine (100 μg), midazolam (100 μg), meropenem
(10 mg), vancomycin (40 mg), propofol (1 mg), dexmede-
tomidine (5 μg), thiopentone (20 mg), ceftriaxone
(50 mg), linezolid (10 mg), ciprofloxacin (5 mg), flucona-
zole (10 mg), and caspofungin (5 mg) were injected post-
oxygenator as a single bolus. The drugs with known
incompatibilities to study drugs (for example, gentamicin
and ticarcillin/clavulunate) were excluded. These bolus
doses were selected to produce concentrations similar to
clinical concentrations. Larger doses were used for the
drugs that exhibit high protein binding.
Controls
Four polyvinylchloride jars with tight caps were filled with
50 mL of fresh human whole blood. Unfractionated
heparin (500 U) was added to the jars for anticoagulation.
Fentanyl (1.5 μg), morphine (7.5 μg), midazolam (7.5 μg),
meropenem (0.75 mg), vancomycin (3 mg), propofol
(75 μg), dexmedetomidine (0.375 μg), thiopentone
(1.5 mg), ceftriaxone (3.75 mg), linezolid (0.75 mg), cipro-
floxacin (0.375 mg), fluconazole (0.75 mg), and caspofun-
gin (0.375 mg) were added to the control jars after
collection of baseline blood samples. These amounts were
chosen in order to produce study drug concentrations that
were similar to those achieved in the ECMO circuit. The
jars were then placed in an incubator at 37°C and rocked
continuously to ensure even distribution of the drugs.
Blood sample collection
Post-oxygenator blood was collected into lithium heparin
tubes (5 mL) at baseline and at 2, 5, 15, 30, 60, 120, and
360 minutes and at 12 and 24 hours after addition of the
drugs to the circuit. Blood samples (5 mL) were also
obtained from the control jars at time intervals identical
to that of the circuit. All blood samples were stored on
ice and centrifuged (10 minutes at 3,000g), and the
plasma was separated and stored in clean pre-labeled
polypropylene cryogenic vials and stored at -80°C until
analysis.
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Measurement of drugs in plasma samples
An on-line solid-phase extraction (SPE) Symbiosis
Pharma system (Spark Holland, Emmen, The Nether-
lands) was used to extract the analytes of interest (fenta-
nyl, morphine, and midazolam) and two internal
standards (morphine-d3 and 1-hydroxymidazolam-d5)
from plasma samples simultaneously [17]. Mass spectro-
metry in ESI (electrospray ionization) mode (API 5500;
AB Sciex, Framingham, MA, USA) triple quadropole sys-
tem was used as the detector. Liquid chromatography
and extraction method were created by Symbiosis Pro for
Analyst (version 2.1.0.0) and submitted to the MS con-
trolling software (Analyst 1.5.1). Meropenem and vanco-
mycin concentrations in the collected plasma samples
were determined by separate validated chromatographic
assay methods. Meropenem and the internal standard
(cefotaxime) were detected by ultraviolet absorbance at
304 nm. Vancomycin analysis was by liquid chromatogra-
phy-tandem mass spectrometry on an Applied Biosys-
tems API2000 (Applied Biosystems, Foster City, CA,
USA) with Shimadzu autosampler (Shimadzu Corpora-
tion, Kyoto, Japan). Vancomycin and the internal stan-
dard (teicoplanin) were detected by positive-mode MRM
(multiple reaction monitoring). All samples were assayed
alongside calibration standards and quality control sam-
ples and met the acceptance criteria.
Statistical analysis
Linear mixed effects modeling was used to examine the
change in concentration over time. This model accounts
for the repeated responses from the same circuit by using
a random intercept. The mixed effects model was fitted
by using the R statistical software [18] version 2.13.2 and
the ‘lme4’ library. The concentration-versus-time curves
(mean ± standard error of the mean) were plotted by
using GraphPad Prism version 5.03 (GraphPad Software,
Inc., La Jolla, CA, USA).
Results
The ex vivo circuits were maintained under physiological
conditions for 24 hours with no complications during the
run. Four hundred samples (80 per drug) were analyzed.
The changes in drug concentrations in the ex vivo model
are summarized in Figures 1 and 2, and the actual drug
concentrations determined in plasma samples from the
control jars and the ECMO circuits are presented in
Table 1. In this paper, only the data for fentanyl, mor-
phine, midazolam, meropenem, and vancomycin are pre-
sented. Validated assays are being developed for the
remaining study drugs, and the results will be made avail-
able in due course.
Testing confirmed that all baseline plasma samples
were free of study drugs. There were no statistically sig-
nificant differences in drug recoveries between the four
circuits. The mean drug recoveries from the circuits and
the control jars at 24 hours relative to baseline were,
respectively, fentanyl 3% and 82%, morphine 103% and
97%, midazolam 13% and 100%, meropenem 20% and
42%, and vancomycin 90% and 99%. Up to 70% of fenta-
nyl and 50% of midazolam were lost in the circuit
within the first hour of ECMO run. Fentanyl levels were
undetectable in the circuit by 24 hours. This may be
related to the lipophilicty of these drugs. Morphine,
which is less lipophilic than fentanyl, was stable in both
the circuit and the controls. Antibiotics were less signifi-
cantly affected. The hydrophilic and minimally protein-
bound drug meropenem was stable in the circuit and
the controls in the first 120 minutes, and 62% of the
drug was recovered from the circuit at 6 hours. This
was statistically significant (P = 0.01) even after account-
ing for spontaneous degradation (21%). There was no
significant loss of the moderately protein-bound hydro-
philic drug vancomycin in the circuit at 12 hours (P =
0.41) or 24 hours (P = 0.26).
Discussion
This is the first systematic investigation of drug disposi-
tion in the adult ECMO circuitry. The findings highlight
the role of the circuit in altering the PK of sedative,
analgesic, and antibiotic drugs during ECMO and clearly
show that there is considerable between-drug variability
in the degree of drug sequestration. Drugs that are
unstable at physiological temperature (meropenem) and
lipophilic drugs (fentanyl and midazolam) were more sig-
nificantly affected. These findings may have significant
implications for both the choice and the dosing of a par-
ticular drug prescribed during ECMO. Given the ongoing
exteriorization of blood onto the circuit during ECMO,
in vivo instability of drugs may also play a significant role
in apparent PK during ECMO. By excluding the patient
factors, this ex vivo model provides evidence that the
adult ECMO circuit is not simply a benign conduit for
blood but actively modulates drug PK.
The circuit factors were identical for all drugs. In this
context, it is difficult to determine which of the drug fac-
tors contributed to the significant disparity in the degree
of drug sequestration in the circuit and ex vivo stability.
Differences in molecular size and lipophilicity and the
differences in protein binding may all have contributed
to the findings. This is important as a blanket increase in
doses of all antibiotic drugs to avoid under-dosing with-
out identifying the drugs that are most sequestered by
the ECMO circuit may potentially result in drug toxicity.
Similarly, drug sequestration in the circuit may also
explain the increasing sedation requirements seen in
patients on ECMO [8,9]. Using sedative and analgesic
agents that are highly sequestered in the circuit may
necessitate the use of very high doses of these drugs to
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achieve the desired pharmacological effect and may add
to the associated morbidity [6]. This calls for further
research in this area to improve drug prescription during
ECMO.
Given that meropenem and vancomycin both rely on
time-dependent bacterial killing, the data presented here
on altered antibiotic concentrations may be clinically
relevant and require evaluation in a clinical PK study.
Meropenem is degraded and sequestered significantly in
the circuit beyond 4 to 6 hours. Hence, a more frequent
dosing or use of higher doses may be required to maxi-
mize the time above minimum inhibitory concentration
of the pathogen [19] as demonstrated in a recent clinical
study [20]. Furthermore, administration of meropenem
by infusion is questionable given the instability issues at
room temperatures [21]. The utility of more stable car-
bapenem antibiotics such as doripenem may have to be
explored in future studies. Clinically, there are no data
on meropenem PK in patients receiving ECMO. Neona-
tal studies have uniformly shown an increase in Vd for
vancomycin and a lower CL and consequently a longer
vancomycin half-life [22,23]. Similarly, PK studies in
neonates have shown increased Vd and decreased CL
for morphine, midazolam, and their metabolites during
ECMO [24,25]. The extent to which these PK alterations
during ECMO are related to sequestration of these
drugs in the circuit is currently unclear.
Studies in the neonatal ECMO circuits have demon-
strated significant sequestration of sedative and antibio-
tic drugs in the circuit. Also, there is drug sequestration
variability based on the different circuits, oxygenators,
and pumps used [13]. A recent in vitro study [13]
reported meropenem and vancomycin recovery of 89%
and 67% at 180 minutes in neonatal circuits that used a
centrifugal pump and polypropylene hollow-fiber mem-
brane oxygenators. Whereas the meropenem recovery at
180 minutes is comparable to our results, vancomycin
recovery was much lower in the neonatal circuits. In
contrast, the fentanyl and midazolam circuit losses seen
in this study are consistent with the results of the neo-
natal circuit studies [13,26-28]. Morphine appears to be
relatively stable in both neonatal and adult ECMO cir-
cuits and may be the preferred analgesic during ECMO.
Future clinical studies should compare the efficacy of
different classes of drugs to rationalize sedation and
analgesia during ECMO.
Studies that compare drug losses in clinically used
versus new neonatal circuits have demonstrated signifi-
cant variability in drug sequestration between the used
and new circuits [10,13,28]. Consequently, it is still
unclear whether there is saturation of the drug-binding
sites in the ECMO circuit over time. Similarly, the effect
Figure 1 Percentage of drug remaining in extracorporeal
membrane oxygenation circuits and the controls plotted
against time. Lipohilic drugs such as fentanyl and midazolam were
significantly sequestered in the circuit despite being stable in the
controls. Morphine was relatively stable in both controls and the
circuits.
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of priming with various solutions on drug sequestration
is not well characterized in the available literature. Drug
sequestration in blood-primed circuits has been shown
to be much lower than that in crystalloid-primed cir-
cuits [27]. It is possible that some of the blood compo-
nents may compete with drugs for circuit-binding sites.
Even though ECMO circuits are not routinely primed
with blood prior to their use in adult patients, the cir-
cuits get primed with the patient’s own blood once
ECMO is commenced.
In our study, we tried to replicate the clinical situation
ex vivo which allowed us to study the interactions
between the drug and the device in the absence of dis-
ease-related factors which independently can significantly
alter PK [29,30]. Repeat dose experiments are required in
long-term model systems to estimate the degree of circuit
saturation with time. The concurrent presence of several
other physically compatible study drugs in the circuit and
control jars mimicked the clinical scenario in which
patients receive these drugs concurrently, but the drugs
may have had an impact on competitive binding to blood
proteins or the circuit components. The presence of a
reservoir bladder may have influenced the circuit drug
losses. Similarly, quantification of drug lost in control
jars because of binding of drugs to the polypropylene
container was not feasible. However, the results confirm
the findings of neonatal ECMO circuit studies.
Conclusions
This ex vivo study highlights the role of the ECMO cir-
cuit in altering PK during ECMO. These alterations are
more pronounced for lipophilic drugs and may result in
Figure 2 Percentage of meropenem and vancomycin remaining in extracorporeal membrane oxygenation circuits and the controls
plotted against time. Meropenem was unstable in the controls; however, the extracorporeal membrane oxygenation circuit losses significantly
exceeded the levels of degradation seen in the controls at 6 hours. Vancomycin was stable in both controls and the circuits.
Table 1 Measured study drug concentrations in the control jars and the extracorporeal membrane oxygenation
circuits at 5 minutes and at 1, 6, 12, and 24 hours
Drug, units of concentration 5 minutes 1 hour 6 hours 12 hours 24 hours
C E C E C E C E C E
Fentanyl, ng/mL
Median 27 1 25 0.4 26 0.1 22 0.1 22 0
Range 26-29 1-1 24-25 0.2-0.5 26-28 0-0.2 20-24 0-0.2 20-24 0-0.1
Morphine, ng/mL
Median 136 7 139 8 137 8 139 8 135 8
Range 134-140 6-7 132-141 7-9 134-140 8-9 135-143 8-8 134-141 7-9
Midazolam, ng/mL
Median 134 175 131 117 138 59 124 42 128 31
Range 126-155 144-356 124-137 109-261 127-147 54-124 117-132 41- 96 120-131 30-61
Vancomycin, μg/mL
Median 71 73 70 73 72 71 72 71 69 67
Range 66-80 67-83 69-76 70-86 67-76 69-74 68-74 68-71 67-70 64-70
Meropenem, μg/mL
Median 18 15 17 14 14 10 11 6 7 3
Range 17-18 11-16 16-18 10-15 13-15 7-11 11-11 4-8 7-8 2-5
C, control jars; E, extracorporeal membrane oxygenation circuits.
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therapeutic failure. Morphine may be a useful alternative
to fentanyl in a patient with escalating sedative and
analgesic drug requirements. Less lipophilic sedative
agents may have to be considered in patients receiving
unusually high doses of midazolam. Given the instability
issues and circuit sequestration, meropenem may have
to be dosed more frequently or in higher doses pending
future clinical PK studies. Vancomycin is less signifi-
cantly affected, and therapeutic drug monitoring as cur-
rently practiced can guide optimal treatment. PK studies
in adult patients on ECMO are indicated for future
research in order to generate the data to guide antibio-
tic, sedative, and analgesic therapy during ECMO.
Key messages
• Lipophilic drugs appear to be more significantly
sequestered in the ECMO circuit, although further
study with different lipophilic drugs is required to
confirm this observation.
• Fentanyl and midazolam are more significantly
sequestered than morphine.
• Meropenem may have to be administered more
frequently during ECMO.
• Physical instability of meropenem may affect its
delivery by a continuous infusion.
• Sequestration of drugs in the circuit may have
implications on both the choice and dosing of a par-
ticular drug prescribed during ECMO.
Abbreviations
CL: clearance; ECMO: extracorporeal membrane oxygenation; PK:
pharmacokinetics; PLS: permanent life support; Vd: volume of distribution.
Acknowledgements
This study was supported in part by funding provided by the National
Health and Medical Research Council, the Australian and New Zealand
College of Anaesthetists, the Intensive Care Foundation, The Prince Charles
Hospital Foundation, and the Australian Red Cross Blood Service (the Blood
Service) and Australian governments that fully fund the Blood Service for the
provision of blood products and services to the Australian community. We
thank Suzie Parker-Scott for antibiotic drug assays and Lynette Munck for
assisting with revision of the manuscript.
Author details
1Critical Care Research Group, Adult Intensive Care Services, The Prince
Charles Hospital & The University of Queensland, Rode Road, Chermiside,
Queensland, Australia, 4032. 2Burns Trauma and Critical Care Research
Centre, The University of Queensland, Cnr Butterfield St and Bowen Bridge
Rd, Herston, Queensland, Australia, 4029. 3Institute of Health and Biomedical
Innovation, School of Public Health & Social Work, Queensland University of
Technology, Cnr Musk and Victoria Park Rd, Kelvin Grove, Queensland,
Australia, 4059. 4Centre for Integrated Preclinical Drug Development, Cnr
Butterfield St and Bowen Bridge Rd Herston, The University of Queensland,
Queensland, Australia, 4029.
Authors’ contributions
KS designed and coordinated the study, collected and analyzed data, and
developed the manuscript for publication. CIM provided technical assistance
in setting up the circuits. SF helped with procuring study drugs and
dispensing them. AGB helped with statistical analysis. SG assayed study
drugs midazolam, morphine, and fentanyl. SCW assisted with the control
experiments and antibiotic drug assays. MTS and JAR helped with study
design, data analysis, and manuscript preparation. DVM, YLF, and JFF assisted
with study design, resources, and manuscript preparation. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 19 April 2012 Revised: 2 September 2012
Accepted: 18 September 2012 Published: 15 October 2012
References
1. Bartlett RH, Gattinoni L: Current status of extracorporeal life support
(ECMO) for cardiopulmonary failure. Minerva Anestesiol 2010, 76:534-540.
2. Kollef MH: Inadequate antimicrobial treatment: an important
determinant of outcome for hospitalized patients. Clin Infect Dis 2000,
31(Suppl 4):S131-138.
3. Kollef MH, Sherman G, Ward S, Fraser VJ: Inadequate antimicrobial
treatment of infections: a risk factor for hospital mortality among
critically ill patients. Chest 1999, 115:462-474.
4. Roberts JA, Kruger P, Paterson DL, Lipman J: Antibiotic resistance–what’s
dosing got to do with it? Crit Care Med 2008, 36:2433-2440.
5. Roberts JA, Roberts MS, Semark A, Udy AA, Kirkpatrick CM, Paterson DL,
Roberts MJ, Kruger P, Lipman J: Antibiotic dosing in the ‘at risk’ critically
ill patient: linking pathophysiology with pharmacokinetics/
pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol 2011,
11:3.
6. Patel SB, Kress JP: Sedation and analgesia in the mechanically ventilated
patient. Am J Respir Crit Care Med 2012, 185:486-497.
7. MacLaren G, Combes A, Bartlett RH: Contemporary extracorporeal
membrane oxygenation for adult respiratory failure: life support in the
new era. Intensive Care Med 2012, 38:210-220.
8. Shekar K, Mullany DV, Corley A, Bull T, Fisquet S, Barnett AG, Roberts JA,
Fraser JF: Increased sedation requirements in patients receiving
extracorporeal life support for respiratory and cardio-respiratory failure.
Anaesth Intensive Care 2012, 40:648-655.
9. Shekar K, Roberts JA, Ghassabian S, Mullany DV, Ziegenfuss M, Smith MT,
Fung YL, Fraser JF: Sedation during extracorporeal membrane
oxygenation -why more is less. Anaesth Intensive Care .
10. Bhatt-Meht V, Annich G: Sedative clearance during extracorporeal
membrane oxygenation. Perfusion 2005, 20:309-315.
11. Shekar K, Fraser JF, Smith MT, Roberts JA: Pharmacokinetic changes in
patients receiving extrcorporeal membrane oxygenation. J Crit Care 2012.
12. Buck ML: Pharmacokinetic changes during extracorporeal membrane
oxygenation: implications for drug therapy of neonates. Clin
Pharmacokinet 2003, 42:403-417.
13. Wildschut ED, Ahsman MJ, Allegaert K, Mathot RA, Tibboel D: Determinants
of drug absorption in different ECMO circuits. Intensive Care Med 2010,
36:2109-2116.
14. Roberts JA, Lipman J: Pharmacokinetic issues for antibiotics in the
critically ill patient. Crit Care Med 2009, 37:840-851, quiz 859.
15. Alcorn J, McNamara PJ: Pharmacokinetics in the newborn. Adv Drug Deliv
Rev 2003, 55:667-686.
16. Shekar K, Fung YL, Diab S, Mullany DV, McDonald CI, Dunster KR, Fisquet S,
Platts DG, Stewart D, Wallis SC, Smith MT, Roberts JA, Fraser JF:
Development of simulated and ovine models of ECLS to improve
understanding of circuit-host interactions. Crit Care Resusc 2012,
14:105-111.
17. Ghassabian S, Moosavi SM, Valero YG, Shekar K, Fraser JF, Smith MT: High-
throughput assay for simultaneous quantification of the plasma
concentrations of morphine, fentanyl, midazolam and their major
metabolites using automated SPE coupled to LC-MS/MS. J Chromatogr B
Analyt Technol Biomed Life Sci 2012, 903:126-133.
18. R Development Core Team: R: a language and environment for statistical
computing, reference index version 2.13.2. Vienna, Austria: R Foundation
for Statistical Computing; 2010 [http://www.R-project.org], ISBN 3-900051-
07-0.
19. Varghese JM, Roberts JA, Lipman J: Pharmacokinetics and
pharmacodynamics in critically ill patients. Curr Opin Anaesthesiol 2010,
23:472-478.
Shekar et al. Critical Care 2012, 16:R194
http://ccforum.com/content/16/5/R194
Page 6 of 7
20. Shekar K, Roberts JA, Ghassabian S, Mullany DV, Wallis SC, Smith MT,
Fraser JF: Altered antibiotic pharmacokinetics during extracorporeal
membrane oxygenation: cause for concern? J Antimicrob Chemother .
21. Berthoin K, Le Duff CS, Marchand-Brynaert J, Carryn S, Tulkens PM: Stability
of meropenem and doripenem solutions for administration by
continuous infusion. J Antimicrob Chemother 2010, 65:1073.
22. Mulla H, Pooboni S: Population pharmacokinetics of vancomycin in
patients receiving extracorporeal membrane oxygenation. Br J Clin
Pharmacol 2005, 60:265-275.
23. Amaker RD, DiPiro JT, Bhatia J: Pharmacokinetics of vancomycin in
critically ill infants undergoing extracorporeal membrane oxygenation.
Antimicrob Agents Chemother 1996, 40:1139-1142.
24. Ahsman MJ, Hanekamp M, Wildschut ED, Tibboel D, Mathot RA: Population
pharmacokinetics of midazolam and its metabolites during venoarterial
extracorporeal membrane oxygenation in neonates. Clin Pharmacokinet
2010, 49:407-419.
25. Peters JW, Anderson BJ, Simons SH, Uges DR, Tibboel D: Morphine
metabolite pharmacokinetics during venoarterial extra corporeal
membrane oxygenation in neonates. Clin Pharmacokinet 2006, 45:705-714.
26. Mulla H, Lawson G, von Anrep C, Burke MD, Upton DU, Firmin RK, Killer H:
In vitro evaluation of sedative drug losses during extracorporeal
membrane oxygenation. Perfusion 2000, 15:21-26.
27. Mehta NM, Halwick DR, Dodson BL, Thompson JE, Arnold JH: Potential
drug sequestration during extracorporeal membrane oxygenation:
results from an ex vivo experiment. Intensive Care Med 2007, 33:1018-1024.
28. Dagan O, Klein J, Gruenwald C, Bohn D, Barker G, Koren G: Preliminary
studies of the effects of extracorporeal membrane oxygenator on the
disposition of common pediatric drugs. Ther Drug Monit 1993, 15:263-266.
29. Lipman J, Udy AA, Roberts JA: Do we understand the impact of altered
physiology, consequent interventions and resultant clinical scenarios in
the intensive care unit? The antibiotic story. Anaesth Intensive Care 2011,
39:999-1000.
30. Ulldemolins M, Roberts JA, Lipman J, Rello J: Antibiotic dosing in multiple
organ dysfunction syndrome. Chest 2011, 139:1210-1220.
doi:10.1186/cc11679
Cite this article as: Shekar et al.: Sequestration of drugs in the circuit
may lead to therapeutic failure during extracorporeal membrane
oxygenation. Critical Care 2012 16:R194.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Shekar et al. Critical Care 2012, 16:R194
http://ccforum.com/content/16/5/R194
Page 7 of 7
